Aytu BioPharma Inc

Research Aytu BioPharma Inc (AYTU) on Bullrun: market cap USD 25.22M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 25.22M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 66.38M-USD 13.56M-USD 2.17M69.0%-3.08USD 30.95MUSD 12.75MUSD 18.97M
FY2024USD 65.18M-USD 15.84M-USD 1.72M75.3%-3.79USD 20.01MUSD 12.73MUSD 27.72M
FY2023USD 107.40M-USD 17.05Mn/a62.0%-5.11USD 22.99MUSD 14.80MUSD 39.36M
FY2022USD 96.67M-USD 108.78M-USD 28.82M54.1%-74.01USD 19.36MUSD 18.81MUSD 44.31M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 25.22Mn/an/an/a
20252025-12-31USD 27.91Mn/an/an/a
20242024-12-31USD 10.49Mn/an/an/a
20232023-12-29USD 15.81Mn/an/an/a
20222022-12-30USD 11.86Mn/an/an/a
20212021-12-31USD 40.51Mn/an/an/a

About Aytu BioPharma Inc

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Aytu BioPharma Inc's market cap?

Aytu BioPharma Inc's market capitalization is USD 25.22M.

What does Aytu BioPharma Inc do?

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD.